Publications by authors named "Aml A Mahfouz"
Article Synopsis
- Childhood cancer survivors have a higher risk of hepatitis C virus (HCV) infection, and the effects of all-oral direct-acting antiviral therapy (DAA) on this population have not been thoroughly studied.
- A study involved 20 children with chronic HCV genotype-4 who were in remission from hematologic malignancies and treated with a combination of sofosbuvir and daclatasvir (SOF/DCV) for 12 weeks.
- The results showed a 100% success rate in achieving sustained virologic response, normalization of liver enzymes, and no serious adverse events, indicating that SOF/DCV therapy is safe and effective for treating chronic HCV in these children.
Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected adolescents, 12-17 years of age, were treated with sofosbuvir/daclatasvir therapy for 12 weeks. The intent-to-treat sustained virologic response rate at 12 weeks after end of treatment was 39/40 (97.
View Article and Find Full Text PDFObjectives: Dual sofosbuvir/daclatasvir (SOF/DCV) therapy is currently recommended by the European Association for Study of Liver (EASL) as an option for the treatment of chronic hepatitis C virus (HCV) infection in adults for all genotypes; however, it is still not considered for patients younger than 18 years old. We aimed to test safety and efficacy of SOF/DCV in adolescent patients 12 to 17 years old with chronic HCV, genotype 4 infection.
Methods: We conducted a prospective, uncontrolled, open-label multicenter study.